- HTG Molecular Diagnostics Inc Key Opinion Leader (KOL) “The Role of RNA Profiling in Drug Discovery and Analysis” - Corporate Call TranscriptDec 13, 2022
- Q2 2022 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 11, 2022$13.56Earnings
- HTG Molecular Diagnostics Inc Host a Key Opinion Leader (KOL) Webinar TranscriptJul 27, 2022
- Q1 2022 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 12, 2022$7.32 (+1.48%)Earnings
- Q4 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 29, 2022$19.08 (+2.58%)Earnings
- Q3 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 10, 2021$60.12 (-3.65%)Earnings
- Q2 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 12, 2021$72.48 (-0.82%)Earnings
- Q1 2021 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 13, 2021$44.64 (-5.10%)Earnings
- Q4 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 25, 2021$68.04 (+3.66%)Earnings
- Q3 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 10, 2020$59.51 (-1.52%)Earnings
- Q2 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 11, 2020$117.36 (+1.87%)Earnings
- Q1 2020 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 13, 2020$65.36 (-9.47%)Earnings
- Q4 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 25, 2020$60.3 (-4.29%)Earnings
- HTG Molecular Diagnostics, Inc. - Special Call TranscriptDec 13, 2019
- Q3 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptNov 12, 2019$140.49 (-3.22%)Earnings
- HTG Molecular Diagnostics, Inc. - Special Call TranscriptOct 29, 2019
- Q2 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptAug 06, 2019$248.4 (+1.47%)Earnings
- Q1 2019 HTG Molecular Diagnostics Inc Earnings Call TranscriptMay 09, 2019$446.4 (+1.22%)Earnings
- Q4 2018 HTG Molecular Diagnostics Inc Earnings Call TranscriptMar 07, 2019$469.8 (-0.76%)Earnings
HTG Molecular Diagnostics, Inc. - Special Call Transcript
All right. I think we're going to get going. Sorry for the fan noise, we're trying to get that turned off right now. But -- so first of all, I'd like to welcome everyone here and also everyone on the webcast. My name is John Lubniewski, I'm the President and the CEO of HTG Molecular. I'm joined by my colleagues, Dr. Maureen Cronin, who is our Chief Science Officer; Laura Beggrow, who is our President of Diagnostics; and our special guest, Dr. Adam Brufsky from the University of Pittsburgh, School of Medicine. So thank you Dr. Brufsky. Safe harbor.
Here is our program. I'm going to open with a few words about HTG and our overall business and then I'm going to detail our initial initiatives in breast cancer. Hopefully, you'll find it exciting. I think you're going to find this as somewhat breakthrough thinking in regards to diagnostics. And then I'm going to introduce Dr. Brufsky who will present his perspective on breast cancer testing and then we'll open up the floor for questions.
So with that, I'd like
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)